[1]
Y. Yamashita, “Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em&gt; overexpression”, Hematol Rep, vol. 12, no. 1, May 2020.